Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Emtricitabine

FDA-approved product (capsule, oral), marketed as Emtricitabine, Emtriva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Emtricitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Emtricitabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Emtricitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01495702 · start 2011-12

    Registered record
    Registry ID
    NCT01495702
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    NNRTI; FTC/TDF; Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-12
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionNNRTI; FTC/TDF; Stribild
    PhasePhase 3
    Registry statusCompleted

  • Effects of Intensive cART During Acute/Early HIV Infection

    NCT01154673 · start 2011-11

    Registered record
    Registry ID
    NCT01154673
    Conditions
    Acute HIV Infection
    Interventions
    raltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-09
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute HIV Infection
    Interventionraltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression

    NCT01471821 · start 2011-10

    Registered record
    Registry ID
    NCT01471821
    Conditions
    HIV Infection
    Interventions
    antiretroviral treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-10
    Completion
    2014-04
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    Interventionantiretroviral treatment
    PhasePhase 4
    Registry statusCompleted

  • The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1

    NCT01451333 · start 2011-09

    Registered record
    Registry ID
    NCT01451333
    Conditions
    HIV Infection
    Interventions
    Efavirenz; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionEfavirenz; Efavirenz
    PhasePhase 3
    Registry statusCompleted

  • Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

    NCT01061151 · start 2011-03-01

    Registered record
    Registry ID
    NCT01061151
    Conditions
    HIV Infections
    Interventions
    Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV); Lopinavir-ritonavir (LPV-RTV); Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Nevirapine (NVP): Infant short-course; Nevirapine (NVP): Infant extended; No Intervention; Discontinue triple ARVs; Continue triple ARVs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03-01
    Completion
    2016-09-30
    Enrolment
    3,747

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV) +7 more
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

    NCT00799864 · start 2011-01

    Registered record
    Registry ID
    NCT00799864
    Conditions
    HIV-1
    Interventions
    Rilpivirine; Zidovudine; Abacavir; Tenofovir disoproxil fumarate; Lamivudine; Emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-01
    Completion
    2022-08
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionRilpivirine; Zidovudine; Abacavir; Tenofovir disoproxil fumarate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

    NCT01140880 · start 2010-05

    Registered record
    Registry ID
    NCT01140880
    Conditions
    HIV Seroconversion; Stimulant Abuse
    Interventions
    Truvada
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-05
    Completion
    2013-03
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Seroconversion; Stimulant Abuse
    InterventionTruvada
    PhasePhase 2
    Registry statusCompleted

  • Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy

    NCT02097381 · start 2010-04

    Registered record
    Registry ID
    NCT02097381
    Conditions
    HIV Infection
    Interventions
    Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2010-04
    Completion
    2014-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionTenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
    PhaseNot applicable
    Registry statusUnknown

  • Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

    NCT00949234 · start 2010-03

    Registered record
    Registry ID
    NCT00949234
    Conditions
    HIV Prevention; HIV Infections
    Interventions
    tenofovir + emtricitabine, lopinavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-08
    Enrolment
    267

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Prevention; HIV Infections
    Interventiontenofovir + emtricitabine, lopinavir/ritonavir
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients

    NCT00943540 · start 2009-07

    Registered record
    Registry ID
    NCT00943540
    Conditions
    HIV Infection; HIV Infections
    Interventions
    raltegravir QD; atazanavir; lamivudine (or emtricitabine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2011-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; HIV Infections
    Interventionraltegravir QD; atazanavir; lamivudine (or emtricitabine)
    PhasePhase 2
    Registry statusCompleted

  • Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment

    NCT00737724 · start 2008-03

    Registered record
    Registry ID
    NCT00737724
    Conditions
    HIV; AIDS; Tuberculosis
    Interventions
    Simultaneous ARV and antiMTB; Deferred RV and antiMTB treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2008-03
    Completion
    2011-02
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS; Tuberculosis
    InterventionSimultaneous ARV and antiMTB; Deferred RV and antiMTB treatment
    PhaseNot applicable
    Registry statusTerminated

  • Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)

    NCT00705419 · start 2007-07

    Registered record
    Registry ID
    NCT00705419
    Conditions
    HIV Infections
    Interventions
    Vicriviroc maleate; Vicriviroc maleate; Placebo; Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-07
    Completion
    2010-09
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionVicriviroc maleate; Vicriviroc maleate; Placebo; Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg
    PhaseNot recorded
    Registry statusCompleted

  • KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects

    NCT00549198 · start 2007-06

    Registered record
    Registry ID
    NCT00549198
    Conditions
    Infection, Human Immunodeficiency Virus I; HIV Infection
    Interventions
    Abacavir/lamivudine and efavirenz; Tenofovir/Emtricitabine and efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-06
    Completion
    2009-12
    Enrolment
    392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus I; HIV Infection
    InterventionAbacavir/lamivudine and efavirenz; Tenofovir/Emtricitabine and efavirenz
    PhasePhase 4
    Registry statusCompleted

  • ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

    NCT00335322 · start 2007-02

    Registered record
    Registry ID
    NCT00335322
    Conditions
    Human Immunodeficiency Virus (HIV)
    Interventions
    Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-02
    Completion
    2011-11
    Enrolment
    329

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV)
    InterventionTruvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    PhasePhase 4
    Registry statusCompleted

  • Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children

    NCT00364793 · start 2007-02

    Registered record
    Registry ID
    NCT00364793
    Conditions
    HIV Infections
    Interventions
    Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2013-07
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEfavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
    PhasePhase 1 / Phase 2
    Registry statusCompleted